Search - tctmd.com

Displaying 1 - 20 of 140

Sort: Relevancy | Date

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

November 14, 2025

Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials

News Conference News AHA 2025

Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials

Yael L. Maxwell

November 13, 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

News Conference News AHA 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

Yael L. Maxwell

November 12, 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

AI-Powered Digital Stethoscope Detects Low EF in Patients With HF Symptoms

News Conference News AHA 2025

AI-Powered Digital Stethoscope Detects Low EF in Patients With HF Symptoms

November 10, 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

News Conference News AHA 2025

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

November 09, 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

November 08, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

What’s Going to Be Hot at AHA 2025?

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

News Conference News AHA 2024

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

November 22, 2024

Infections No More Likely With Reconditioned Versus New Pacemakers

News Conference News AHA 2024

Infections No More Likely With Reconditioned Versus New Pacemakers

Yael L. Maxwell

November 22, 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

Talking Sex: CVD Patients Want to Hear More From Clinicians

News Conference News AHA 2024

Talking Sex: CVD Patients Want to Hear More From Clinicians

November 20, 2024

AI Poised to Change the Landscape of Echocardiography

News Conference News AHA 2024

AI Poised to Change the Landscape of Echocardiography

Yael L. Maxwell

November 19, 2024

Extreme Heat Seems to Spark More Atrial Arrhythmias in IED Patients

News Conference News AHA 2024

Extreme Heat Seems to Spark More Atrial Arrhythmias in IED Patients

November 19, 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

November 18, 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

News Conference News AHA 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

Yael L. Maxwell

November 18, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.